AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35303932 — intervention group
Group type: COMPARATOR
Intervention: Conventional rigid obturator prosthesis
Number of subjects: 14
Study 32809899 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (135-140 beats per minute)
Number of subjects: 20
Study 32809899 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 20
Study 35343933 — intervention group
Group type: EXPERIMENTAL
Intervention: Subparaneural upper trunk block (5 mL of 0.5% ropivacaine)
Number of subjects: 96
Study 35343933 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block (15 mL of 0.5% ropivacaine)
Number of subjects: 96
Study 35343933 — intervention group
Group type: EXPERIMENTAL
Intervention: Subparaneural upper trunk block
Number of subjects: 96
Study 35343933 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 96
Study 34195679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 175
Study 34195679 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 175
Study 36314032 — intervention group
Group type: EXPERIMENTAL
Intervention: Active + MM (anodal tDCS + mindfulness meditation)
Number of subjects: 30
Study 36314032 — intervention group
Group type: COMPARATOR
Intervention: Sham + MM (sham tDCS + mindfulness meditation)
Number of subjects: 30
Study 36314032 — intervention group
Group type: COMPARATOR
Intervention: NoT (no intervention)
Number of subjects: 30
Study 36314032 — intervention group
Group type: EXPERIMENTAL
Intervention: Active + MM
Number of subjects: 30
Study 36314032 — intervention group
Group type: COMPARATOR
Intervention: Sham + MM
Number of subjects: 30
Study 36314032 — intervention group
Group type: COMPARATOR
Intervention: NoT
Number of subjects: 30
Study 32702309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (350 mg/m2 once daily for patients <18 years; 600 mg once daily for patients ≥18 years)
Number of subjects: 81
Study 32702309 — intervention group
Group type: COMPARATOR
Intervention: Control (no pazopanib)
Number of subjects: 81
Study 32702309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 81
Study 32702309 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 81
Study 32702309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib and Control
Number of subjects: 81
Study 36369034 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic (RAL) Heller myotomy
Number of subjects: 43
Study 36369034 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic (LSC) Heller myotomy
Number of subjects: 43
Study 33335310 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 (100 mg)
Number of subjects: 43
Study 33335310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 32867830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers.
Number of subjects: 0
Study 32867830 — intervention group
Group type: COMPARATOR
Intervention: Prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy).
Number of subjects: 0
Study 33543797 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense formula (100 mL, 2 kcal/mL)
Number of subjects: 18
Study 33543797 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (200 mL, 1 kcal/mL)
Number of subjects: 18
Study 33290192 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 120
Study 33290192 — intervention group
Group type: COMPARATOR
Intervention: Control group (breast milk)
Number of subjects: 120
Study 33248560 — intervention group
Group type: EXPERIMENTAL
Intervention: DTUMV + dIL-2
Number of subjects: 55
Study 33248560 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/2DTUMV + dIL-2
Number of subjects: 55
Study 33248560 — intervention group
Group type: COMPARATOR
Intervention: DTUMV
Number of subjects: 55
Study 33248560 — intervention group
Group type: COMPARATOR
Intervention: 1/2DTUMV
Number of subjects: 55
Study 33248560 — intervention group
Group type: COMPARATOR
Intervention: PBS
Number of subjects: 55
Study 36307059 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 103
Study 36307059 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 103
Study 33600539 — intervention group
Group type: EXPERIMENTAL
Intervention: Abutment screws retightened 10 minutes after initial torque application
Number of subjects: 158
Study 33600539 — intervention group
Group type: COMPARATOR
Intervention: Abutment screws not retightened 10 minutes after initial torque application
Number of subjects: 158
Study 32506227 — intervention group
Group type: EXPERIMENTAL
Intervention: FTL-assisted delivery of topical tranexamic acid (TXA)
Number of subjects: 46
Study 32506227 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 46
Study 36313769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on a Mediterranean diet (IG)
Number of subjects: 2418
Study 36313769 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 2418
Study 36313769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention group (IG)
Number of subjects: 2418
Study 36313769 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world group (RW)
Number of subjects: 2418
Study 36313769 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian variants
Number of subjects: 2418
Study 36313769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic variants
Number of subjects: 2418
Study 32868704 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray examination (AP and PA projections)
Number of subjects: 240
Study 35940932 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial hand sanitizer
Number of subjects: 90
Study 35940932 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor solution
Number of subjects: 90
Study 35940932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 34161360 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) and solifenacin succinate
Number of subjects: 86
Study 34161360 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin succinate alone
Number of subjects: 86
Study 35613402 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki sessions conducted by trained and experienced Reiki masters, lasting between 45 and 90 minutes.
Number of subjects: 1284
Study 33882779 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated visual acuity (VA) impairments
Number of subjects: 33
Study 33882779 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated contrast sensitivity (CS) impairments
Number of subjects: 33
Study 33882779 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated visual field (VF) impairments
Number of subjects: 33
Study 33882779 — intervention group
Group type: COMPARATOR
Intervention: Clear goggle (no impairment) trials
Number of subjects: 33
Study 34602386 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (DCB)
Number of subjects: 50
Study 34602386 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 50
Study 34766389 — intervention group
Group type: EXPERIMENTAL
Intervention: M. officinalis capsules (400 mg/d; n = 23)
Number of subjects: 49
Study 34766389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 49
Study 35505375 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord-derived mesenchymal stem cells (UC-MSCs)
Number of subjects: 91
Study 35505375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 32940750 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-arm fiberglass cast (SAC)
Number of subjects: 120
Study 32940750 — intervention group
Group type: COMPARATOR
Intervention: Long-arm cast (LAC)
Number of subjects: 120
Study 35041636 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen 5/325 mg
Number of subjects: 347
Study 35041636 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen/acetaminophen 600/325 mg
Number of subjects: 347
Study 33197662 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil applied three times a day for five days after chemotherapy in addition to routine antiemetic treatment.
Number of subjects: 0
Study 33197662 — intervention group
Group type: COMPARATOR
Intervention: Routine antiemetic treatment only (Control group).
Number of subjects: 0
Study 35870902 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide combined with intravenous hydrocortisone hemisuccinate (n = 23)
Number of subjects: 50
Study 35870902 — intervention group
Group type: COMPARATOR
Intervention: Normal saline combined with intravenous hydrocortisone hemisuccinate (n = 27)
Number of subjects: 50
Study 35870902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (budesonide and control)
Number of subjects: 50
Study 33683070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 1%-Tretinoin 0.025% (CT)
Number of subjects: 20
Study 33683070 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl Peroxide 2.5%-Adapalene 0.1% (BA)
Number of subjects: 20
Study 34498068 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g IV acetaminophen every six hours for 48 hours postoperatively
Number of subjects: 154
Study 34498068 — intervention group
Group type: COMPARATOR
Intervention: IV placebo every six hours for 48 hours postoperatively
Number of subjects: 154
Study 34498068 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g IV acetaminophen
Number of subjects: 154
Study 34498068 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 154
Study 35866206 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone delivered intervention (seven telephone calls, fortnightly, plus a booster session at 16 weeks)
Number of subjects: 76
Study 35866206 — intervention group
Group type: COMPARATOR
Intervention: Information only (control group)
Number of subjects: 76
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Ability Index
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Disability Assessment Schedule 2.0
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Quality of Life-BREF questionnaire
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal and cardiovascular diseases
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation of the workplace to functional and health-related needs
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological well-being
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 201
Study 33223538 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of chronic diseases
Number of subjects: 201
Study 32079342 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) following the SWEP method
Number of subjects: 129
Study 32079342 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 129
Study 35818157 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy for pollen; 3 years of treatment.
Number of subjects: 10
Study 35818157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy for grass pollen, house-dust mite, or Japanese cedar; duration not specified.
Number of subjects: 10
Study 35818157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sublingual and subcutaneous grass pollen immunotherapies; 2 years of treatment.
Number of subjects: 10
Study 33602945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 30
Study 33602945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35636467 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical masks
Number of subjects: 45
Study 35636467 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2 masks
Number of subjects: 45
Study 35636467 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no mask)
Number of subjects: 45
Study 35636467 — intervention group
Group type: COMPARATOR
Intervention: Post-baseline (no mask)
Number of subjects: 45
Study 33766760 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care model of psychological care (low intensity CBT program: Internet-delivered or work-at-home book with brief therapist calls)
Number of subjects: 666
Study 36364765 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking speed of 20 mL/5 min
Number of subjects: 18
Study 36364765 — intervention group
Group type: COMPARATOR
Intervention: Drinking speed of 40 mL/5 min
Number of subjects: 18
Study 36364765 — intervention group
Group type: COMPARATOR
Intervention: Drinking speed of 80 mL/5 min
Number of subjects: 18
Study 32653359 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 64
Study 32653359 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded mother's voice
Number of subjects: 64
Study 32653359 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMuffs
Number of subjects: 64
Study 32653359 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 34218069 — intervention group
Group type: EXPERIMENTAL
Intervention: e-book (n=33)
Number of subjects: 66
Study 34218069 — intervention group
Group type: COMPARATOR
Intervention: video and brochure (n=33)
Number of subjects: 66
Study 32580063 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a strapped standard helmet
Number of subjects: 479892
Study 32580063 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing an unstrapped standard helmet
Number of subjects: 479892
Study 34536404 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 496
Study 34536404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 34428832 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (7 days of oral intake)
Number of subjects: 43
Study 34428832 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 43
Study 36005837 — intervention group
Group type: EXPERIMENTAL
Intervention: BREAK (interrupting 4 hr of sitting with 4 min of light body‐weighted resistance activity every 30‐min)
Number of subjects: 17
Study 36005837 — intervention group
Group type: EXPERIMENTAL
Intervention: BREAK
Number of subjects: 17
Study 36005837 — intervention group
Group type: COMPARATOR
Intervention: SIT (4 hr of uninterrupted sitting)
Number of subjects: 17
Study 36005837 — intervention group
Group type: COMPARATOR
Intervention: SIT
Number of subjects: 17
Study 33942989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient group
Number of subjects: 30
Study 33942989 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 36455058 — intervention group
Group type: EXPERIMENTAL
Intervention: MD/DO
Number of subjects: 126
Study 36455058 — intervention group
Group type: COMPARATOR
Intervention: DO/DO
Number of subjects: 126
Study 36455058 — intervention group
Group type: COMPARATOR
Intervention: MD/MD
Number of subjects: 126
Study 33093119 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-SAL
Number of subjects: 2652
Study 34047697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram140/90
Number of subjects: 6201
Study 34047697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram130/80
Number of subjects: 6201
Study 32565594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg daily
Number of subjects: 30
Study 32565594 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 20 mg daily
Number of subjects: 30
Study 32565594 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 75 mg daily
Number of subjects: 30
Study 36367768 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 136
Study 36367768 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal incision
Number of subjects: 136
Study 33560411 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ghrelin administration
Number of subjects: 0
Study 33560411 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study 32809002 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model (12 months of self-management support, decision support electronic health records, specialist case reviews)
Number of subjects: 404
Study 32809002 — intervention group
Group type: COMPARATOR
Intervention: Usual care (24 months)
Number of subjects: 404
Study 32809002 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 404
Study 32809002 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study 35586130 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraformaldehyde based pulpal medicament
Number of subjects: 82
Study 33704530 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 41
Study 33704530 — intervention group
Group type: COMPARATOR
Intervention: standard induction chemotherapy
Number of subjects: 41
Study 33039693 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (0.1 mg, 0.2 mg, 0.4 mg)
Number of subjects: 320
Study 33039693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 33039693 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 320
Study 35362776 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent-based techniques (n = 26)
Number of subjects: 74
Study 35362776 — intervention group
Group type: EXPERIMENTAL
Intervention: Consequent-based techniques (n = 25)
Number of subjects: 74
Study 35362776 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (n = 23)
Number of subjects: 74
Study 33384215 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled surgical caps
Number of subjects: 20
Study 33384215 — intervention group
Group type: COMPARATOR
Intervention: Nonlabeled surgical caps
Number of subjects: 20
Study 33002704 — intervention group
Group type: EXPERIMENTAL
Intervention: Anx/Dep+CB group
Number of subjects: 42
Study 33002704 — intervention group
Group type: COMPARATOR
Intervention: Anx/Dep-lowCB group
Number of subjects: 42
Study 33002704 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 42
Study 33002704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop Signal Task (SST)
Number of subjects: 42
Study 35775365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 15
Study 35775365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 33322936 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable Training Group (UTG)
Number of subjects: 77
Study 33322936 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable Training Group (STG)
Number of subjects: 77
Study 33322936 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 77
Study 33573854 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) staging
Number of subjects: 254
Study 36059000 — intervention group
Group type: COMPARATOR
Intervention: Copy number alterations
Number of subjects: 300
Study 36059000 — intervention group
Group type: COMPARATOR
Intervention: Copy number loss
Number of subjects: 300
Study 36059000 — intervention group
Group type: COMPARATOR
Intervention: Loss of segments in chromosome 5q21‐22 and gains at 8q21‐24
Number of subjects: 300
Study 36059000 — intervention group
Group type: COMPARATOR
Intervention: Variability of copy number alterations across tumour regions
Number of subjects: 300
Study 34363051 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based transcutaneous electrical acupoint stimulation (TEAS) for 12 weeks, 4 weekly sessions
Number of subjects: 60
Study 34363051 — intervention group
Group type: COMPARATOR
Intervention: Usual care (continuation of antihypertensive drugs and lifestyle education)
Number of subjects: 60
Study 32639394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate (KF) 5 mg orally twice daily for 6 weeks
Number of subjects: 151
Study 32639394 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo (PL) orally twice daily for 6 weeks
Number of subjects: 151
Study 32639394 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 151
Study 32639394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 151
Study 32639394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate (KF)
Number of subjects: 151
Study 32639394 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo (PL)
Number of subjects: 151
Study 34186535 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (part of a randomized controlled trial)
Number of subjects: 462
Study 33217860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 108
Study 33217860 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 108
Study 35081130 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Acceptance and Commitment Therapy (ACT)
Number of subjects: 314
Study 35081130 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 314
Study 33582687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 0
Study 33582687 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 35578403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep continuity disruption (n = 27)
Number of subjects: 51
Study 35578403 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sleep (n = 24)
Number of subjects: 51
Study 34737470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (n=1987)
Number of subjects: 4108
Study 34737470 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=1966)
Number of subjects: 4108